XFOR Adam R Craig buys $250K worth of shares
Oct 28, 2025, 4:36 AM
0.00%
What does XFOR do
X4 Pharmaceuticals, based in Boston, focuses on developing novel therapies for rare diseases, particularly those related to immune dysfunction. Its lead candidate, mavorixafor, targets chemokine receptor CXCR4, with additional pre-clinical candidates in development.
Adam R Craig bought 86,206 shares of XFOR on 23 October at $2.90 per share, worth a total of $250K. They now own 376,087 XFOR shares, or a 30% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.